Published in J Clin Endocrinol Metab on September 01, 2000
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet (2013) 5.57
Advances in osteoporosis therapy. 2003 update of practical guidelines. Can Fam Physician (2003) 2.09
Osteoporosis in men. Endocr Rev (2008) 1.80
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int (2013) 1.79
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab (2010) 1.77
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor. Proc Natl Acad Sci U S A (2012) 1.50
Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int (2011) 1.33
PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res (2011) 1.30
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab (2014) 1.20
Bone fragility in men--where are we? Osteoporos Int (2006) 1.19
Teriparatide (1-34 human PTH) regulation of osterix during fracture repair. J Cell Biochem (2008) 1.16
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
A review of anabolic therapies for osteoporosis. Arthritis Res Ther (2003) 1.14
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int (2004) 1.13
Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest (2011) 1.12
Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab (2012) 1.08
Recombinant human parathyroid hormone. BMJ (2002) 1.06
The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int (2004) 1.05
Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int (2005) 1.00
Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab (2009) 0.99
Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab (2013) 0.98
Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res (2010) 0.96
Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. J Clin Endocrinol Metab (2014) 0.94
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int (2007) 0.94
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab (2012) 0.92
Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit (2011) 0.91
Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int (2007) 0.90
Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women. Postgrad Med J (2002) 0.89
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Osteoporosis in the aging male: treatment options. Clin Interv Aging (2007) 0.87
Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. Bone (2010) 0.87
Causes, consequences, and treatment of osteoporosis in men. Drug Des Devel Ther (2013) 0.87
Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab (2006) 0.87
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int (2013) 0.87
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int (2007) 0.86
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Comparison of dried plum supplementation and intermittent PTH in restoring bone in osteopenic orchidectomized rats. Osteoporos Int (2007) 0.86
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int (2006) 0.85
Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int (2015) 0.84
Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int (2005) 0.84
Osteoporosis. Postgrad Med J (2002) 0.82
Osteoporosis in men. J R Soc Med (2001) 0.82
The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice. Endocrinology (2008) 0.82
Therapy of osteoporosis in men with teriparatide. J Osteoporos (2011) 0.81
Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report. Clin Interv Aging (2016) 0.81
Osteoporotic fracture and parathyroid hormone. World J Orthop (2011) 0.81
The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men. J Osteoporos (2011) 0.80
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PLoS One (2015) 0.80
Chronic kidney disease and the skeleton. Bone Res (2014) 0.79
Biochemical bone turnover markers and osteoporosis in older men: where are we? J Osteoporos (2011) 0.79
Short-Term Effects of Kefir-Fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in a Randomized Clinical Trial of Osteoporotic Patients. PLoS One (2015) 0.79
Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis (2011) 0.79
Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. Osteoporos Int (2006) 0.78
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment. Clin Interv Aging (2008) 0.78
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab (2009) 0.78
A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia. Osteoporos Int (2014) 0.77
Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone. Bone Res (2014) 0.77
Male osteoporosis: clinical approach and management in family practice. Singapore Med J (2014) 0.77
Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med (2015) 0.76
Present at the beginning: a personal reminiscence on the history of teriparatide. Osteoporos Int (2011) 0.76
Current Role and Application of Teriparatide in Fracture Healing of Osteoporotic Patients: A Systematic Review. J Bone Metab (2017) 0.75
Safety and effectiveness of teriparatide vs alendronate in postmenopausal osteoporosis: a prospective non randomized clinical study. Clin Cases Miner Bone Metab (2017) 0.75
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc (2016) 0.75
Bone Mineral Density Response from Teriparatide in Patients with Osteoporosis. HSS J (2017) 0.75
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med (1999) 4.91
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet (1976) 4.24
Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med (1997) 3.91
Genetic variability in adult bone density among inbred strains of mice. Bone (1996) 3.66
HIV disease and the endocrine system. N Engl J Med (1992) 3.48
Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int (2007) 3.12
Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00
An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94
Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6J and C3H/HeJ inbred strains of mice. J Bone Miner Res (2001) 2.94
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab (1999) 2.79
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr (1998) 2.37
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Prevention of spinal osteoporosis in oophorectomised women. Lancet (1980) 2.34
Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) (2009) 2.28
Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J Neurosci (1983) 2.18
Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab (1998) 2.14
Anabolic actions of parathyroid hormone on bone. Endocr Rev (1993) 2.13
Adipogenesis is inhibited by brief, daily exposure to high-frequency, extremely low-magnitude mechanical signals. Proc Natl Acad Sci U S A (2007) 2.04
Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology (2008) 2.03
Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab (2000) 2.00
Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res (1997) 1.98
Fracture history and bone loss in patients with MS. Neurology (1998) 1.97
Pathogenesis of osteoporosis. Lancet (1993) 1.93
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology (2000) 1.93
Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab (1996) 1.92
Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology (2008) 1.89
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc (1999) 1.84
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Importance of precision in bone density measurements. J Clin Densitom (2001) 1.82
Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract (2001) 1.81
The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol (1984) 1.80
Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J (1973) 1.79
Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab (1995) 1.79
Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol (2003) 1.74
Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int (2010) 1.74
Mechanism of tryptophanase induction in Escherichia coli. J Mol Biol (1967) 1.71
Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med (1974) 1.69
Quantitative trait loci for bone density in C57BL/6J and CAST/EiJ inbred mice. Mamm Genome (1999) 1.68
The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab (2008) 1.67
Whole-body vibration slows the acquisition of fat in mature female rats. Int J Obes (Lond) (2008) 1.64
Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63
Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) (1974) 1.63
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Biochemistry, genetics, and applications of exopolysaccharide production in Streptococcus thermophilus: a review. J Dairy Sci (2003) 1.60
Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab (1998) 1.58
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
Neuropsychometric changes in patients after carotid endarterectomy. Stroke (1998) 1.57
Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab (1998) 1.56
High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology (1994) 1.54
Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab (2007) 1.53
On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 1.53
Progeston therapy for menstrually related aphthae. Int J Oral Surg (1978) 1.52
Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int (2009) 1.52
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51
The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev (1983) 1.51
Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med (1978) 1.50
Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab (1998) 1.49
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int (2008) 1.44
Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone (2007) 1.43
Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician (2000) 1.43
New insights into osteoporosis: the bone-fat connection. J Intern Med (2012) 1.43
The hypothalamus-pituitary-adrenal axis in HIV disease. AIDS Read (2003) 1.42
Exogenous calciferol (vitamin D) and vitamin D endocrine status among elderly nursing home residents in the New York City area. J Am Geriatr Soc (1993) 1.42
Constant mineralization density distribution in cancellous human bone. Bone (2003) 1.41
Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab (1996) 1.41
Incidence of atrial fibrillation after mild or moderate hypothermic cardiopulmonary bypass. Crit Care Med (2000) 1.40
The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med (1999) 1.40
Primary hyperparathyroidism: still evolving? J Bone Miner Res (1997) 1.39
Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med (1990) 1.39
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
Bone response to termination of oestrogen treatment. Lancet (1978) 1.38
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
The redistribution of body sodium in women on long-term oestrogen therapy. Clin Sci Mol Med (1974) 1.38
Interaction of calcium nutrition and physical activity on bone mass in young women. J Bone Miner Res (1988) 1.37